Search

Your search keyword '"Vitulo, Patrizio"' showing total 279 results

Search Constraints

Start Over You searched for: Author "Vitulo, Patrizio" Remove constraint Author: "Vitulo, Patrizio"
279 results on '"Vitulo, Patrizio"'

Search Results

2. Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus

3. Right ventricular phenotyping in incident patients with idiopathic pulmonary arterial hypertension

4. Serologic screening and molecular surveillance of Kaposi sarcoma herpesvirus/human herpesvirus-8 infections for early recognition and effective treatment of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome in solid organ transplant recipients

6. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension

7. Tixagevimab/Cilgavimab as SARS-CoV-2 Pre-Exposure Prophylaxis in Lung Transplant Recipients during the Omicron Wave: A Real-World Monocentric Experience.

11. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial

12. Pathogenesis, clinical features and phenotypes of pulmonary hypertension associated with interstitial lung disease A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension

14. 121 RELEVANCE OF COMORBIDITIES ON INITIAL COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION

17. Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting

19. Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant Recipients

20. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

21. Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension

23. Chronic thromboembolic pulmonary hypertension risk score evaluation and validation (CTEPH SOLUTION): proposal of a study protocol aimed to realize a validated risk score for early diagnosis

27. Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection

28. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

29. Psychological counselling interventions to improve perceived quality of life and counter anxiety and depression in pulmonary-arterial-hypertension patients: A clinical trial

30. The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease

31. The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?

41. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints:Aconsensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative--Group 3 Pulmonary Hypertension.

42. Risk reduction and hemodynamics with initial combination therapy in pulmonary arterial hypertension

45. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension

46. Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

50. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy

Catalog

Books, media, physical & digital resources